Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

Blood–brain barrier (BBB) disruption, mediated through matrix metalloproteinases (MMPs)
and other mechanisms, is a critical event during ischemic stroke. Tissue plasminogen …

Today there exists only one FDA-approved treatment for ischemic stroke; ie, the serine
protease tissue-type plasminogen activator (tPA). In the aftermath of the failed stroke clinical …

Blood-brain barrier (BBB) leakage and brain edema is a critical part of stroke
pathophysiology. In this mini-review, we briefly survey the potential role of matrix …

Blood–brain barrier (BBB) disruption occurs early enough to be within the thrombolytic time
window, and this early ischemic BBB damage is closely associated with hemorrhagic …

The blood-brain barrier (BBB) is a vital component of the neurovascular unit (NVU)
containing tight junctional (TJ) proteins and different ion and nutrient transporters which …

Numerous studies have documented increases in matrix metalloproteinases (MMPs),
specifically MMP-9 levels following stroke, with such perturbations associated with …

Ischemic stroke is a disease with high morbidity and mortality worldwide, which often places
an additional strain on families and society due to the poor prognosis. Blood brain-barrier …

Matrix metalloproteinases (MMPs) mediate tissue injury during acute stroke. Clinical data
show that elevated MMPs in plasma of stroke patients may correlate with outcomes …

Background and Purpose—Matrix metalloproteinases (MMPs) have a central role in
compromising the integrity of the blood–brain barrier (BBB). The role of MMP-12 in brain …